Two RET inhibitors, selpercatinib and pralsetinib, are the standard treatment option for RET-driven thyroid carcinomas as well as for RET-rearranged non-small cell lung cancers [63,66]. The gene discussed is RET; the disease is non-small cell lung carcinoma.